How common is hair loss on semaglutide?

Uncommon, and more frequent than placebo. The pooled pivotal trials put it at 3.3% on 2.4 mg — 4% of women and 0.9% of men — against 1% on placebo. In the higher-dose trials it reached 6% at 7.2 mg. Among adolescents aged 12 and older it was 4%, with no placebo cases reported.

When does semaglutide hair loss usually start?

If the shedding is telogen effluvium, it typically becomes noticeable about two to three months after the trigger, and up to four months where a shortfall in intake is involved. The trigger is usually a period of fast weight loss or restricted eating rather than the date of the first dose, so the timing often surprises people.

Will hair grow back after semaglutide-related shedding?

Usually, if the cause is an acute telogen effluvium and the trigger resolves — around 95% of acute cases remit. Regrowth cannot be promised for an individual, though. Visible density lags behind the shedding phase, and ongoing restriction, thyroid disease, iron deficiency or pattern hair loss can change the course.

Should I stop semaglutide because my hair is shedding?

Not without discussing it with the prescriber first. Stopping may not halt shedding quickly, because follicles already in the resting phase shed weeks later regardless. A prescriber can review the pace of weight loss, food intake, competing causes and the pattern itself, then decide whether to hold an escalation, adjust the maintenance dose, continue, or change course.

Is semaglutide hair loss more common in women?

Yes, that was the pattern in the trials. The pooled data report hair loss in 4% of women and 0.9% of men on semaglutide 2.4 mg, against 2% of women and no men on placebo; in the higher-dose trials it was 8.4% of women at 7.2 mg. Those are trial reports, not an explanation of the difference.

Does Semaglutide Cause Hair Loss?

Yes, hair loss can happen during semaglutide treatment, and it shows up in the trial record: across the pooled 68-week weight-management trials, hair loss was reported by 3% of adults taking semaglutide 2.4 mg against 1% of those on placebo. The careful way to answer "does semaglutide cause hair loss" is that treatment is associated with more shedding reports than placebo, while the mechanism that best fits the evidence is telogen effluvium after rapid weight loss and reduced food intake, rather than a direct effect on the hair follicle.

That distinction is not pedantry. A trial can show that shedding happened more often during treatment without showing what caused it in any one person — the molecule, the pace of the weight change, a much smaller diet, or something already underway.

Does semaglutide cause hair loss in the clinical trials?

Hair loss was uncommon in the semaglutide programme, and consistently more frequent than placebo. The figures below come from the current prescribing information for branded semaglutide, which pools the three pivotal 68-week weight-management trials — the STEP 1 obesity trial, the type 2 diabetes trial, and the intensive-lifestyle trial.

Trial population	Semaglutide	Placebo
Adults on 2.4 mg weekly, pooled (N=2,116 vs 1,261)	3.3% — 4% of women, 0.9% of men	1% — 2% of women, 0 men
Adults in the higher-dose trials	6% at 7.2 mg; 3% at 2.4 mg	1%
Adolescents aged 12 and older (N=133 vs 67)	4%	0%

Those are adverse-event reports, not dermatologist-confirmed diagnoses, and the trials were not designed to establish why the shedding happened — they cannot separate a drug effect from a weight effect.

Independent evidence points the same way. A 2026 systematic review and meta-analysis in Diabetes Research and Clinical Practice pooled nine interventional studies covering 4,114 people treated with GLP-1 receptor agonists. It found a risk ratio of 3.25 for hair loss against placebo (95% CI 1.44 to 7.36), rising to 3.59 (2.10 to 6.12) when restricted to randomised trials in overweight and obesity, with a single-arm event rate of 3.9%. A tripled relative risk on a low absolute rate is still a low absolute rate — but it is a signal, not noise. Semaglutide side effects covers the rest of the tolerability picture.

Why weight loss explains it better than a follicle effect

The labelling says so plainly: hair-loss reactions in treated patients "were associated with weight reduction". Three strands support that reading.

The reporting rate tracks the dose, and the dose tracks the weight. In the higher-dose trials the rate ran 1% on placebo, 3% at 2.4 mg and 6% at 7.2 mg, and the sex split widened with it: 8.4% of women at 7.2 mg against 5.4% at 2.4 mg. The change involved is not small: in STEP 1, published in the New England Journal of Medicine, mean body weight fell 14.9% over 68 weeks against 2.4% on placebo.

The diabetes doses look different. On the branded semaglutide product used at 0.5 to 2 mg for type 2 diabetes, alopecia appears only in the postmarketing section, not in the trial adverse-reaction table — though that table has a 5% reporting floor and would not have surfaced a 3% signal anyway. Suggestive rather than conclusive, and consistent with less weight change producing less shedding. How semaglutide works covers the dose difference.

The mechanism predates these medicines by decades. Telogen effluvium is diffuse, non-scarring shedding that begins when a physiological stressor pushes an abnormal share of follicles out of the growing phase and into the resting phase. A review of telogen effluvium in Cureus lists severe protein, fatty-acid and zinc deficiency, chronic starvation and caloric restriction among its established triggers. Reduced intake is the bridge: semaglutide lowers appetite, and persistent nausea, early fullness or a much smaller plate make adequate protein, energy and micronutrients harder to hold on to.

None of that closes the case. A direct effect on the follicle has not been excluded — the meta-analysis authors call for prospective work for that reason. The weight-and-intake explanation simply has more behind it.

The two-to-four month lag, and why shedding usually settles

Telogen effluvium runs on the hair cycle, not the injection calendar. The Cureus review puts the usual delay at two to three months after the trigger, and notes that shedding traced to essential fatty acid deficiency appears two to four months after intake falls short. The trigger is often a stretch of fast weight loss or thin eating well before hair began collecting in the shower.

What happens	When	What it means
The trigger	Weeks to months before any shedding	Rapid weight loss, restricted intake, illness, surgery or major stress shifts follicles into the resting phase
Visible shedding	Usually about 2–3 months later	Diffuse loss across the scalp, most obvious during washing or brushing
Acute course	Under 6 months, by definition	Around 95% of acute cases remit; shedding past six months is chronic and deserves a fresh look

That is the typical sequence, not a forecast. The trials published no onset-to-recovery curve, and continuing restriction, an untreated thyroid problem, iron deficiency, or a pattern hair loss the shedding has made visible will each change the course.

Is this specific to semaglutide?

It is not. Hair loss is reported across the GLP-1 class rather than for one molecule. Tirzepatide's obesity trials show the same shape — low single-digit percentages, higher than placebo, markedly more common in women — with reported rates running roughly 3% to 7% against about 1% on placebo. Close enough to semaglutide's 3% that a shared driver is the sensible reading; does tirzepatide cause hair loss works through those numbers. What both share is how much weight comes off and how fast, which is why the same shedding is described after bariatric surgery and after severe dieting.

What a prescriber can look at, and what they can change

A prescriber has more options than continue or stop. Four things are worth putting in front of them.

The pace of the weight change. Maintenance dosing is selected on response and tolerability, so holding an escalation or settling at a lower maintenance dose is a real lever when weight is falling fast. The dose is the prescriber's decision — the semaglutide dosage schedule explains how that progression is normally handled.

What is actually being eaten. Persistent nausea, vomiting or a very small intake can leave protein and energy short in a way no dose adjustment fixes.

Competing causes. Depending on history and examination, a clinician may check a complete blood count, ferritin and iron studies, or thyroid function. Recent illness, childbirth, surgery, major stress, other medicines and family pattern belong in the timeline too.

Whether the pattern fits. Diffuse shedding with a normal-looking scalp fits telogen effluvium. Patchy loss, scalp pain, redness or scale, many short broken hairs, or a steadily widening part does not. Dermatology referral is the reasonable next step when the pattern is unclear or shedding runs past six months.

What this article deliberately will not do is name a treatment for the shedding, because the evidence does not support one at a distance. A review of diet, nutrient deficiency and hair loss in Dermatology Practical & Conceptual concludes that documented deficiencies should be corrected, that supplementing without one has no established benefit, and that some supplements risk worsening hair loss or causing toxicity. Testing before treating is the point.

At Promise, a licensed provider reviews every request and not everyone qualifies. Where semaglutide is prescribed, that provider is the person to bring shedding to, and can reassess rather than leaving you to reason it out from a forum thread.

Where the compounded formulation sits

Every figure above comes from trials of branded products. At Promise, semaglutide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Compounded preparations are not reviewed by the FDA for safety, effectiveness, or quality. Those rates describe the branded preparations that were studied, not a compounded one.

That is regulatory fact, stated neutrally rather than as a warning. A licensed provider may still prescribe a compounded formulation where they judge it appropriate — that decision is between you and your doctor.

The honest summary is narrow. Semaglutide carries a low but measurable rate of hair-loss reports — around 3% against 1% on placebo, concentrated in women, rising with dose. Telogen effluvium driven by how much weight comes off and how little goes in is the best-supported explanation, and it is why shedding tends to show up two to three months in and usually settles. If your hair is thinning, hand the timeline to someone who can test rather than guessing.